Ayala Pharmaceuticals Announces Completion of Enrollment in

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 patients were enrolled. ”Completion of enrollment in RINGSIDE represents a significant milestone in the development of AL102,” said Kenneth Berlin, President and Chief Executive Officer of Ayala. “There

Related Keywords

Rehovot , Hamerkaz , Israel , Tim Mccarthy , Lifesci Advisors , Ayala Pharmaceuticals , Ayala Pharmaceuticals Inc , Kenneth Berlin , Chief Executive Officer , New Drug Application , Fast Track Designation , Orphan Drug Designation , Sci Advisors , Springside , Desmoid Tumors , Clinical Trial , Clinical Investigators , Nyala , Pharmaceuticals ,

© 2025 Vimarsana